Century Therapeutics updates investor deck highlighting pipeline, Allo-Evasion 3.0, and cash runway into 2026

Century Therapeutics, Inc.

Cash, cash equivalents and investments of $301M at Q2 2023; runway extends into 2026.
ELiPSE-1 trial for CNTY-101 (iNK CD19) ongoing; initial data expected by end of 2023, PoC in 2024.
Pipeline includes CNTY-102 (iT CD19/CD22 dual-target) and CNTY-107 (iT Nectin-4); BMS collaboration for CNTY-104 (AML) and CNTY-106 (myeloma).
Allo-Evasion 3.0 incorporates 4 edits (β2M KO, CIITA KO, HLA-E KI, HLA-G KI) to protect against NK cell killing.
CNTY-101 designed with Allo-Evasion to enable repeat dosing without additional lymphodepletion; first CD19 agent with this approach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.